Wapner on Avastin

Always interesting and engaging, Jessica Wapner has discussed the bevacizumab (Avastin) saga and a recent recommendation made to the FDA that the drug is not appropriate for the treatment of breast cancer. It is a difficult example because the drug is prohibitively expensive, will evoke a positive response in a relatively small proportion of patients, … Continue reading Wapner on Avastin

Another approved drug may leave the market

Bevacizumab Treatment for Solid Tumors, February 2, 2011, Hayes 305 (5): 506 — JAMA Avastin is a really expensive (think 50K a year) and dangerous (people die more often) drug that has been shown to have marginal positive effects on the progression of cancer for some patients. It is a very difficult question to weigh … Continue reading Another approved drug may leave the market

Ioannidis strikes again

“The need to consider the wider agenda in systematic reviews and meta-analysis: breadth, timing, and depth of the evidence.” Ioannidis and colleague are at it once again, looking at the quality of evidence that gives rise to the approval and eventual widespread use of clinical pharmaceuticals. In this case, they show that a common cancer … Continue reading Ioannidis strikes again